Cite

HARVARD Citation

    Wu, Y. et al. (2019). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of oncology. p. 1019. [Online]. 
  
Back to record